Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964300 | 0.98 | LMNA (0.42) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL1298190 | 0.90 | MEN1 (0.41) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL20530413 | 0.84 | LMNA (0.39) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL28834457 | 0.84 | LMNA (0.39) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL8896948 | 0.82 | ACACB (0.38) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL1836223 | 0.82 | TDP1 (0.43) | FFAR1CPT2TDP1 | |
| SCHEMBL1834842 | 0.82 | TDP1 (0.43) | FFAR1CPT2TDP1 | |
| SCHEMBL7863984 | 0.82 | TDP1 (0.43) | FFAR1CPT2TDP1 | |
| SCHEMBL29219042 | 0.81 | OPRM1 (0.48) | LMNACYP3A4 | |
| SCHEMBL598505 | 0.79 | TSHR (0.32) | MEN1CYP3A4ALOX15KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885MEN1 4055/4885CYP3A4 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.